4.6 Article Proceedings Paper

KAPPA-OPIOID ANTAGONISTS FOR PSYCHIATRIC DISORDERS: FROM BENCH TO CLINICAL TRIALS

Journal

DEPRESSION AND ANXIETY
Volume 33, Issue 10, Pages 895-906

Publisher

WILEY-BLACKWELL
DOI: 10.1002/da.22500

Keywords

anxiety; anxiety disorders; mood disorders; substance use disorders; pharmacotherapy; treatment

Funding

  1. [MH063266]
  2. [HHS-N271-2012-000006-I]

Ask authors/readers for more resources

Kappa-opioid receptor (KOR) antagonists are currently being considered for the treatment of a variety of neuropsychiatric conditions, including depressive, anxiety, and substance abuse disorders. A general ability to mitigate the effects of stress, which can trigger or exacerbate these conditions, may explain their putative efficacy across such a broad array of conditions. The discovery of their potentially therapeutic effects evolved from preclinical research designed to characterize the molecular mechanisms by which experience causes neuroadaptations in the nucleus accumbens (NAc), a key element of brain reward circuitry. This research established that exposure to drugs of abuse or stress increases the activity of the transcription factor CREB (cAMP response element binding protein) in the NAc, which leads to elevated expression of the opioid peptide dynorphin that in turn causes core signs of depressive-and anxiety-related disorders. Disruption of KORs-the endogenous receptors for dynorphin-produces antidepressantand anxiolytic-like actions in screening procedures that identify standard drugs of these classes, and reduces stress effects in tests used to study addiction and stress-related disorders. Although interest in this target is high, prototypical KOR antagonists have extraordinarily persistent pharmacodynamic effects that complicate clinical trials. The development of shorter acting KOR antagonists together with more rapid designs for clinical trials may soon provide insight on whether these drugs are efficacious as would be predicted by preclinical work. If successful, KOR antagonists would represent a unique example in psychiatry where the therapeutic mechanism of a drug class is understood before it is shown to be efficacious in humans. (C) 2016 Wiley Periodicals, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available